Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain.

Abstract:

AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK, USA and Spain, were interviewed on their experiences and views of VKA therapy. Thematic analysis was conducted on the data. RESULTS:Although there were some differences between the countries and some small differences between atrial fibrillation and venous thromboembolism respondents, many respondents found various aspects of VKA to be burdensome, including the international normalized ratio monitoring and dietary considerations. CONCLUSION:Atrial fibrillation and venous thromboembolism respondents accept the limitations of VKAs and the adjustments to their lifestyles, but recognize a lack of alternative treatment.

authors

Wild D,Murray M,Donatti C

doi

10.1586/erp.09.48

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

467-74

issue

5

eissn

1473-7167

issn

1744-8379

journal_volume

9

pub_type

杂志文章
  • New management of the pregnant patient to reduce the risk of transmitting herpes to the newborn.

    abstract::Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.6.783

    authors: Baker DA

    更新日期:2005-12-01 00:00:00

  • Valuing inter-sectoral costs and benefits of interventions in the healthcare sector: methods for obtaining unit prices.

    abstract:INTRODUCTION:There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits' (ICBs). The objective of this study was to develop methods for obtaining unit prices for the valuat...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.2016.1141679

    authors: Drost RM,Paulus AT,Ruwaard D,Evers SM

    更新日期:2017-02-01 00:00:00

  • National trends in out-of-pocket prescription drug spending among elderly medicare beneficiaries.

    abstract::This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.3.297

    authors: Sambamoorthi U,Akincigil A,Wei W,Crystal S

    更新日期:2005-06-01 00:00:00

  • Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.

    abstract:INTRODUCTION:Trastuzumab, the standard treatment for HER-2 positive breast cancer, may be associated with access restrictions in countries with severe economic constraints. This study aimed to compare intravenous (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2019.1554437

    authors: Inotai A,Ágh T,Karpenko AW,Zemplényi A,Kaló Z

    更新日期:2019-04-01 00:00:00

  • Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease.

    abstract::Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.8.2.111

    authors: Gladman DD,Brown RE

    更新日期:2008-04-01 00:00:00

  • Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban.

    abstract::This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.1.49

    authors: Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

    更新日期:2007-02-01 00:00:00

  • Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

    abstract:INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1485099

    authors: Vergnenègre A,Chouaïd C

    更新日期:2018-10-01 00:00:00

  • Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan.

    abstract:OBJECTIVE:To assess the cost-effectiveness of single pill fixed dose triple combination therapy vs. free triple combination therapy for the prevention of cardiovascular events among patients with hypertension. METHODS:A Markov model with a five year cycle was constructed. Two decision models incorporating strict and m...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2020.1800457

    authors: Wang X,Chen H,Ej E,Wu J,Serna O,Paranjpe R,Abughosh S

    更新日期:2020-08-01 00:00:00

  • Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies?

    abstract::The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients categorized into severity groups according to the Expanded Disability St...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.6.2.145

    authors: Orlewska E

    更新日期:2006-04-01 00:00:00

  • Management and costs of severe psoriasis: the role of new biologics.

    abstract::It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.5.573

    authors: Feldman SR,Pearce DJ

    更新日期:2004-10-01 00:00:00

  • Assessing the equality of means of healthcare costs.

    abstract::The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.5.561

    authors: Zhou XH,Ramsey S

    更新日期:2003-10-01 00:00:00

  • Price comparison of high-cost originator medicines in European countries.

    abstract:BACKGROUND:In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-incom...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2016.1223543

    authors: Vogler S,Zimmermann N,Babar ZU

    更新日期:2017-04-01 00:00:00

  • A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.

    abstract::Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2016.1135740

    authors: Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

    更新日期:2016-01-01 00:00:00

  • The process of reconciliation: evaluation of guidelines for translating quality-of-life questionnaires.

    abstract::Reconciliation refers to the process through which two or more independent forward translations are merged into one single translation. This critical step in the translation process is difficult to formalize. The purpose of this review is to analyze how reconciliation is specified in leading guidelines for the transla...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.11.102

    authors: Koller M,Kantzer V,Mear I,Zarzar K,Martin M,Greimel E,Bottomley A,Arnott M,Kuliś D,ISOQOL TCA-SIG.

    更新日期:2012-04-01 00:00:00

  • The START study: when to start to treat with inhaled steroids in asthma?

    abstract::Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/14737167.3.3.223

    authors: Antoniu SA

    更新日期:2003-06-01 00:00:00

  • Persistence with medication and overactive bladder: an ongoing challenge.

    abstract:INTRODUCTION:For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence to medications, losing many people who might benefit from treatment and exposing them to unnecessary ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2016.1203258

    authors: Wagg A

    更新日期:2016-08-01 00:00:00

  • Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.

    abstract::The aim of this systematic review was to collect all current data on indirect costs related to inflammatory bowel disease as well as assessing homogeneity and comparability, and conducting a meta-analysis. Costs were collected using databases from Medline, Embase and Centre for Reviews and Dissemination databases, the...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737167.2015.1011130

    authors: Kawalec P,Malinowski KP

    更新日期:2015-04-01 00:00:00

  • The German method for setting ceiling prices for drugs: in some cases less data are required.

    abstract::The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.11.45

    authors: Gandjour A,Gafni A

    更新日期:2011-08-01 00:00:00

  • How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3).

    abstract:INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2016.1246961

    authors: Wijnen B,Van Mastrigt G,Redekop WK,Majoie H,De Kinderen R,Evers S

    更新日期:2016-12-01 00:00:00

  • Health related quality of life impact from rotavirus diarrhea on children and their family caregivers in Thailand.

    abstract:BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,多中心研究

    doi:10.1080/14737167.2018.1386561

    authors: Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

    更新日期:2018-04-01 00:00:00

  • Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment.

    abstract::Up to 10% of the adult population in most countries may be affected by chronic bronchitis or chronic obstructive pulmonary disease. The course of the disease is characterized by frequent exacerbations with increased respiratory symptoms. Exacerbations are the most important cause of morbidity and mortality, and signif...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.5.4.423

    authors: Miravitlles M

    更新日期:2005-08-01 00:00:00

  • Short- and long-term HRQOL issues following brachytherapy for prostate cancer.

    abstract::Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.4.3.277

    authors: D'haese S,Bottomley A

    更新日期:2004-06-01 00:00:00

  • Global cost modeling analysis of HIV-1 and HCV viral load assays.

    abstract::This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effectiv...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.3.4.383

    authors: Elbeik T,Chen YM,Soutchkov SV,Loftus RA,Beringer S

    更新日期:2003-08-01 00:00:00

  • Patient satisfaction instruments for cancer clinical research or practice.

    abstract::Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/erp.10.7

    authors: Brédart A,Sultan S,Regnault A

    更新日期:2010-04-01 00:00:00

  • Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.

    abstract:INTRODUCTION:In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public ...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1080/14737167.2017.1277144

    authors: Kwon SH,Park SK,Byun JH,Lee EK

    更新日期:2017-08-01 00:00:00

  • Cost analysis and clinical applicability of the Resonance metallic ureteral stent.

    abstract::The Resonance metallic stent is a new wire-based ureteral stent that was initially developed for patients with malignant ureteral obstruction. Potential advantages over traditional stents include resistance to encrustation and to external compression, allowing for increased dwell times and the maintenance of upper tra...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/erp.09.74

    authors: Polcari AJ,Hugen CM,López-Huertas HL,Turk TM

    更新日期:2010-02-01 00:00:00

  • Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease.

    abstract::Alzheimer's disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer's disease. A modeled cost-effectiveness analysis found that treatment with donepezil to be less costly and mor...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 评论,杂志文章

    doi:10.1586/erp.12.21

    authors: Oremus M,Tarride JE

    更新日期:2012-06-01 00:00:00

  • Patient-reported outcomes measurements in epilepsy.

    abstract::This review was designed to explore and review the range of patient-reported outcomes used to assess people with epilepsy. Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations u...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章

    doi:10.1586/14737167.7.4.373

    authors: Stafford M,Gavriel S,Lloyd A

    更新日期:2007-08-01 00:00:00

  • The cost-effectiveness of therapies to treat alcohol use disorders.

    abstract:INTRODUCTION:Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. AREAS COVERED:We searched the literature for the co...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1080/14737167.2018.1392241

    authors: Rehm J,Barbosa C

    更新日期:2018-02-01 00:00:00

  • The minimum clinically important difference for EQ-5D index: a critical review.

    abstract::The European Quality of Life-5 Dimensions Questionnaire (EQ-5D) is the most common instrument to value health outcomes under the patient's perspective. Several studies have investigated whether observed changes are meaningful to patients, using a variety of approaches to estimate the minimum clinically important diffe...

    journal_title:Expert review of pharmacoeconomics & outcomes research

    pub_type: 杂志文章,评审

    doi:10.1586/14737167.2014.894462

    authors: Coretti S,Ruggeri M,McNamee P

    更新日期:2014-04-01 00:00:00